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Background/Objective: Past studies have found a correlation between the Dermatology Life Quality Index
(DLQI) and the Psoriasis Area and Severity Index (PASI) for Caucasian psoriasis patients. This study
examined the relationships between health state utility and willingness to pay (WTP) and the DLQI, as
well as between the PASI and the DLQI, health-related utilities, and WTP in Taiwanese patients.
Methods: A total of 480 psoriasis patients from ﬁve hospitals across Taiwan were interviewed between
August 2009 and February 2010. Health state utilities were elicited using the time trade-off (TTO)
method, a visual analog scale (VAS), and the EuroQOL-ﬁve dimensions (EQ-5D). WTP for a cure was
elicited by double-bounded binary-choice questions followed by a bidding game. Psoriasis severity was
graded as mild (PASI < 3), moderate, or severe (PASI  10).
Results: The mean DLQI values for mild (n ¼ 117), moderate (n ¼ 208), and severe (n ¼ 155) psoriasis
were 5.73, 7.62, and 11.29, respectively. The mean health state utilities were 0.87 (EQ-5D), 0.72 (VAS), and
0.74 (TTO). The monthly maximum WTP value was US$145.3e318.8. EQ-5D and VAS scores were
negatively correlated with all DLQI domains. WTP and DLQI also had a strong correlation in the expected
direction. TTO had the weakest correlation with the DLQI. A smaller TTO was found for Taiwanese pa-
tients than for Caucasians. When considering different PASI severity levels, EQ-5D and VAS scores
remained consistent measures for the DLQI, but the correlation between the TTO and DLQI weakened.
Conclusion: The EQ-5D, VAS, and WTP are consistent measures for the DLQI in assessing the well-being
of psoriasis patients in Taiwan.
Copyright © 2016, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Psoriasis is a chronic, noncontagious skin disease with awide range
of prevalences in different ethnic groups. Previous studies have
shown a prevalence rate of 0.226% among Taiwanese people, as
well as a male to female ratio of 2:1. On average, females have a
younger age of onset, while 20% of patients have a family history of
the disease.1,2they have no ﬁnancial or
ject matter or materials dis-
y, National Taiwan University
00, Taiwan.
al Association. Published by ElseviAlthough psoriasis is rarely life threatening, it results in a poor
quality of life (QOL),3e6 with an impact comparable with that of
diabetes.7 In addition to suffering from the physiological effects of
the illness, psoriasis patients have to face psychological issues such
as frustration, helplessness, and lack of self-conﬁdence because of
changes in the appearance of their skin.8 A good correlation be-
tween the severity of psoriasis, measured by the Psoriasis Area and
Severity Index (PASI), and QOL was previously demonstrated in
many pivotal studies investigating Caucasian patients with mod-
erate to severe psoriasis.9 At present, the study instruments used
to measure patients' subjective QOL indexes include generic
instruments short form-36 (SF-36), speciﬁc instruments, health
state utilities, and contingency valuation methods.10,11
The Dermatology Life Quality Index (DLQI) and the SF-36 are the
most frequently used measures. In fact, the recent argument that
higher treatment efﬁcacy of PASI90 (rather than PASI75) should beer Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
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tics.12 Similarly, our own previous study regarding unreimbursed
use of adalimumab for psoriasis also found a DLQI score of 0e1 to
be a critical factor.13 Other measures of health state utilities are
used relatively infrequently. As the various domains of the different
generic and speciﬁc instruments will generate different values, the
use of a multidimensional approach in describing the overall
health-related QOL has advantages in terms of better reﬂecting a
patient's health condition across multiple domains. In addition,
studies showing correlations among these measurements in milder
psoriasis are limited,14,15 and their correlations, if any, among Asian
patients with psoriasis have yet to be investigated. There have only
been a limited number of studies that focused on the correlations
between preference-based scales and health proﬁle-based scales.
For example, Lundberg et al12 compared the relationships among
health state utilities, willingness to pay (WTP), and QOL scales for
366 patients with psoriasis and atopic eczema, but that study did
not take disease severity into account, and there has been, to our
knowledge, no previous study conducted in Asia that has compared
the relationships among the DLQI, health state utilities, andWTP. In
a small case series involving 40 patients, WTP was not correlated
with the severity of psoriasis (as measured by the body surface area
involved).17 In the current study, we examined how different
measures of health state utilities and WTP are related to the DLQI,
and how their correlations vary over differing levels of PASI scores,
among Taiwanese patients with psoriasis.
Methods
Patient interviews
Well-trained nurses carried out face-to-face interviews with 480
psoriasis patients aged at least 20 years, from August 2009 to May
2010, at dermatology outpatient clinics in ﬁve hospitals located in
northern, central, and southern Taiwan after obtaining approval by
the respective institutional review boards. Patients were stratiﬁed
into three severity groups: (1) mild: PASI < 3; (2) moderate:
3  PASI < 10; and (3) severe: PASI  10. The numbers of patients
interviewed in each group were 117, 208, and 155, respectively.
Instruments for outcome measurements
Instruments used during the interviews to measure the patients'
QOL included the following. (1) Dermatology Life Quality Index. The
DLQI is a validated instrument that contains 10 questions that
assess the impact of skin disease on six aspects of QOL (speciﬁcally,
symptoms and feelings, daily activities, leisure, work or school
performance, personal relationships, and treatment).16 The total
score for the DLQI ranges from 0 to 30, with a higher score denoting
greater QOL impairment; a total score of 10 points is associated
with substantial QOL impairment.18 (2) Health state utilities. Three
types of health state utilities were measured in the study19 (i) Vi-
sual analog scale. This is a psychometric scale measurement, scores
for which range from 0 to 100 points, on which respondents self-
report their overall state of health on that day according to their
personal perspective. (ii) Time trade-off: This is a preference-based
utility measure that asks about a respondent's willingness to forego
years of their life in exchange for a state of perfect health. The
maximum number of years a respondent could trade off was
determined by the given respondent's age. It was 50 years for re-
spondents aged 20e30 years and younger, 40 years for those aged
31e40 years, 30 years for those aged 41e50 years, and ﬁnally,
20 years for those aged 51e60 years and older. (iii) EuroQOL-ﬁve
dimensions. The EuroQOL-ﬁve dimensions (EQ-5D) contains ﬁve
questions that measure ﬁve dimensions, namely, mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
The scoring method for the EQ-5D used in our study followed the
scoring formula developed by Dolan and Gudex,20 such that a value
of utility ranging from 0 to 1 would be obtained. (3) Willingness to
pay. The WTP for relief from psoriasis was elicited by double-
bounded binary-choice questions followed by a bidding game
question to determine the maximum WTP, as suggested in prior
studies.21,22 The speciﬁed ﬁrst-bid price was pretested in order to
better capture the extremes of the WTP. In the end, the speciﬁed
ﬁrst-bid prices were divided into 10 subsamples: United States
(US)$15.6, US$31.25, US$62.5, US$93.8, US$125, US$156.3,
US$187.5, US$250, US$312.5, and US$625. Double-bounded binary-
choice questions randomly set a reasonable initial price and then
let the respondents determine theWTP. If a respondent is willing to
pay a given price, the price is set higher for the second inquiry. If a
respondent is unwilling to pay, the price is set lower for the second
inquiry.23
Statistical analysis
First, the distributions of DLQI scores, WTP values, and utility
weights calculated based upon the EQ-5D, visual analog scale
(VAS), and time trade-off (TTO) were reported. Second, correlation
tests were performed to examine the relationships between the
DLQI scores and the utility weights from the EQ-5D, VAS, and TTO
methods, as well as the WTP. As the WTP values elicited from the
double-bounded dichotomous questions were interval censored
with a right-skewed distribution, a log-normal model in the sur-
vival analysis was estimated using the maximum-likelihood
method. The logarithm of the WTP was assumed to be normally
distributed, with a mean comprising a linear function of individual
characteristics. The regression-adjusted WTP (RA-WTP) was
calculated at the sample mean to represent the WTP for relief from
the symptoms of psoriasis among the sampled patients. Finally,
subgroup analyses were performed to investigate differences in the
associations of DLQI scores with the utility weights and WTP be-
tween the different disease severity groups. Descriptive analyses
and correlations were performed using SPSS software, version 16.0
(SPSS Inc., Chicago, IL, USA), and theWTP regressionwas performed
using SAS software, version 9.1 (SAS Institute, Cary, NC, USA).
Results
Characteristics of the patients are shown in Table 1. There were 360
(75.0%) male patients and 120 (25.0%) female patients, and their
average age was 44.52 years. The average disease duration was
10.9 years. In terms of disease severity, 117 (24.4%) respondents had
mild psoriasis (PASI < 3), 208 (43.3%) had moderate psoriasis
(3  PASI < 10), and 155 (32.3%) had severe psoriasis (PASI  10).
Table 2 shows the descriptive statistics for all the QOL measures
stratiﬁed by disease severity. The average score in each dimension
of the DLQI and the mean values of both the maximum WTP and
the RA-WTP increased with the level of disease severity.
Results of the correlation analysis are shown in Table 3, and
indicate that the EQ-5D and VAS were signiﬁcantly correlated with
every dimension (p < 0.01) of the DLQI, with the strongest corre-
lations being with the “symptoms and feelings,” “daily activities,”
and “leisure” dimensions. The TTO was also signiﬁcantly correlated
with the same three dimensions of the DLQI, but to a lesser extent,
while both the “work and school” and the “treatment” dimension
were not signiﬁcantly correlated with the TTO. The RA-WTP was
signiﬁcantly correlated with all the dimensions of the DLQI, with
the strongest correlations being with the “leisure,” “treatment,”
and “daily activities” dimensions. Overall, the health utility mea-
sures and WTP were signiﬁcantly correlated with the overall DLQI
Table 1 Selected patient characteristics.
PASI < 3 3  PASI < 10 PASI  10 All (n ¼ 480)
Mild (n ¼ 117) Moderate (n ¼ 208) Severe (n ¼ 155)
No. % No. % No. % No. %
Gender
Male 73 62 156 89 131 85 360 75
Female 44 38 52 30 24 15 120 25
Age, y, mean ± s.d. 44.77 ± 16.48 44.54 ± 15.06 44.30 ± 13.81 44.52 ± 15.01
Marital status
Single 41 35 73 35 66 43 180 38
Married 76 65 135 65 89 57 300 63
Employment
Full time 62 53 124 60 104 67 290 60
Part time 6 5 9 4 11 7 26 5
Unemployed 49 42 75 36 40 26 164 34
Household monthly income (US$)
<937.5 23 20 26 13 24 15 73 15
937.5e1562.4 27 23 36 17 34 22 97 20
1562.5e2187.4 18 15 44 21 25 16 87 18
2187.5e3124.9 20 17 28 13 36 23 84 18
3125e4687.4 19 16 40 19 19 12 78 16
4687.5e6249.9 3 3 14 7 9 6 26 5
>6250 7 6 20 10 8 5 35 7
Education
Elementary 17 15 23 11 12 8 52 11
Junior high school 12 10 18 9 16 10 46 10
High school 26 22 54 26 50 32 130 27
University 52 44 90 43 64 41 206 43
Graduate school 10 9 23 11 13 8 46 10
Disease history, y, mean ± s.d. 9.35 ± 9.65 10.38 ± 8.85 12.77 ± 8.16 10.9 ± 8.93
PASI¼ Psoriasis Area and Severity Index; s.d. ¼ standard deviation.
Table 2 Health state utilities, DLQI, and WTP stratiﬁed according to PASI levels.
PASI < 3 3  PASI < 10 PASI  10 All cases
Mild (n ¼ 117) Moderate (n ¼ 208) Severe (n ¼ 155) (N ¼ 480)
Mean Median s.d. Mean Median s.d. Mean Median s.d. Mean Median s.d.
Health utility
EQ-5D 0.89 1 0.21 0.9 1 0.15 0.83 0.85 0.2 0.87 1 0.18
VAS 0.75 0.8 0.17 0.75 0.8 0.15 0.67 0.7 0.16 0.72 0.75 0.16
TTO 0.81 0.88 0.25 0.73 0.8 0.28 0.71 0.8 0.28 0.74 0.83 0.27
DLQI
Symptoms & feelings 1.74 2 1.33 2.36 2 1.46 3.03 3 1.47 2.42 2 1.51
Daily activities 0.95 0 1.33 1.31 1 1.39 2.15 2 1.66 1.5 1 1.54
Leisure 1.03 0 1.52 1.37 1 1.43 2.23 2 1.78 1.56 1 1.64
Work & school 0.59 0 0.89 0.77 1 0.86 1.07 1 0.95 0.83 1 0.92
Personal relationships 0.69 0 1.09 0.86 0 1.13 1.5 1 1.51 1.02 1 1.3
Treatment 0.74 1 0.76 0.95 1 0.93 1.32 1 1.03 1.02 1 0.95
Overall DLQI score 5.73 4 5.22 7.62 7 5.26 11.29 11 6.43 8.34 7 6.05
Maximum WTP 145.3 93.8 218.7 261.6 156.3 456.3 318.8 187.5 327.8 254.4 156.3 376.6
Regression-adjusted WTP 166 159.9 67.9 244.7 6978.5 218.1 412.9 395.2 143.1 281.9 249.5 145.8
DLQI ¼ Dermatology Life Quality Index; EQ-5D ¼ EuroQOL-ﬁve dimensions; PASI¼ Psoriasis Area and Severity Index; s.d. ¼ standard deviation; TTO ¼ time trade-off;
VAS ¼ visual analog scale; WTP ¼ willingness to pay.
Table 3 Health state utilities, WTP, and their association with the DLQI among patients with psoriasis.
DLQI Health utilities Willingness to pay*
EQ-5D (n ¼ 480) VAS (n ¼ 480) TTO (n ¼ 480) Maximum WTP (n ¼ 451) Regression-adjusted WTP (n ¼ 451)
Symptoms & feelings 0.348** 0.348** 0.149** 0.046 0.124**
Daily activities 0.352** 0.315** 0.184** 0.077 0.211**
Leisure 0.400** 0.302** 0.167** 0.127** 0.284**
Work & school 0.246** 0.228** 0.06 0.022 0.123**
Personal relationships 0.246** 0.238** 0.184** 0.099* 0.174**
Treatment 0.260** 0.213** 0.065 0.046 0.241**
Overall DLQI score 0.416** 0.369** 0.188** 0.098* 0.257**
* Statistically signiﬁcant at the 0.05 level (2 tailed).
** Statistically signiﬁcant at the 0.01 level (2 tailed).
DLQI ¼ Dermatology Life Quality Index; EQ-5D ¼ EuroQOL-ﬁve dimensions; TTO ¼ time trade-off; VAS ¼ visual analog scale; WTP ¼ willingness to pay.
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weakest correlation with the maximum WTP.
A subgroup analysis showed that the EQ-5D and VAS remained
signiﬁcantly correlated with the DLQI across the three disease
severity groups, with the exception of any associations between the
EQ-5D and the “work and school” dimension for mild cases or
between the VAS and the “personal relationships” and “treatment”
dimensions for severe cases (Tables 4e6). The correlations between
the dimensions of the DLQI and the TTO became weaker in the
subgroup analysis, and some of them did not reach statistical sig-
niﬁcance. The maximumWTP was signiﬁcantly correlated with the
“daily activities,” “leisure,” and “personal relationships” di-
mensions among mild cases, but it was not signiﬁcantly correlated
with the other two dimensions at any severity level or with the
“daily activities,” “leisure,” and “personal relationships” di-
mensions among moderate and severe cases. The strong correla-
tions of all dimensions of the DLQI with the RA-WTP were reduced
in the subgroup analysis. The RA-WTP was signiﬁcantly associated
with the “symptoms and feelings” dimension for both mild and
moderate cases, and with the overall DLQI score for moderate and
severe cases. The RA-WTPwas also signiﬁcantly correlated with the
“work and school” dimension for moderate cases, and with the
“leisure” and “treatment” dimensions for severe cases.
Discussion
Psoriasis has a major impact on patients' QOL. Most early studies on
the health-related QOL of dermatology patients used a single QOL
scale to reﬂect the disease burden on patients24,25 or a QOL scale to
measure certain features before and after treatment.26 Garduno
et al27 conducted a systematic review of studies on health-related
QOL over a recent 5-year period and found that 54.8% of studies
used the DLQI as a measurement instrument. The various domains
of the DLQI are signiﬁcant indicators for dermatology patients.
More recently, health state utilities (such as the EQ-5D, VAS, and
TTO) and contingent valuation methods (such as the WTP) have
also gradually been applied in an increasing number of dermato-
logical studies.12,28e30 Health state utilities and contingent valua-
tion methods have the advantage of using one value to reﬂect an
overall QOL. The disadvantage of these approaches is that they
constitute more complex methods of measurement.18,31e36
Our study examined how different measures of health state
utilities and WTP were related to the DLQI, and how those corre-
lations varied according to the level of PASI scores among Taiwa-
nese patients with psoriasis. Our results showed that the average
score of the EQ-5D among Taiwanese patients was 0.87, which was
higher than 0.75, the average score of the EQ-5D in a German
study.25 Our results also showed that the average score of the VAS
was 0.72, while that of the TTO was 0.74. A study conducted by
Lundberg et al12 on 234 Swiss patients with psoriasis showed that
the average score of the VAS was 0.69, which was similar to that inTable 4 Health state utilities, WTP, and their associations with the DLQI among patients
Health utilities
EQ-5D (n ¼ 117) VAS (n ¼ 117) TTO (n ¼
Symptoms & feelings 0.254** 0.246** 0.181
Daily activities 0.421** 0.286** 0.133
Leisure 0.454** 0.244** 0.210*
Work & school 0.125 0.186* 0.026
Personal relationships 0.210* 0.222* 0.235*
Treatment 0.243** 0.225* 0.025
Overall DLQI score 0.404** 0.317** 0.182*
* Statistically signiﬁcant at the 0.05 level (2 tailed).
** Statistically signiﬁcant at the 0.01 level (2 tailed).
DLQI ¼ Dermatology Life Quality Index; EQ-5D ¼ EuroQOL-ﬁve dimensions; TTO ¼ timeour study, while the average score of the TTO was 0.88, which was
higher than that in our study.
The DLQI domains and the EQ-5D, VAS, and TTOwere negatively
correlated in our study, indicating that lower EQ-5D, VAS, and TTO
scores were associated with higher DLQI scores. The EQ-5D had the
strongest correlations with the DLQI domains, the VAS had the
second strongest correlations, and the TTO had the weakest cor-
relations. Although the TTO has a better theoretical basis than the
VAS, correlations between the TTO and the DLQI domains were
lower than those between the VAS and the DLQI domains. This
might have been due to the fact that the VAS question was more
straightforward and comprehensible for patients to answer than
the TTO question.12,37,38 The psychometric measurement scales had
good reliability and validity, and were easy to use. Moreover, the
fact that the correlations between health state utilities and the
scales have been shown to be high implies that the health state
utilities have higher validity.39,40
An in-depth analysis of the correlations between the DLQI do-
mains and the health utility measures showed that the EQ-5D had a
signiﬁcant negative correlation with each of the DLQI domains
(p < 0.01). This indicated that lower EQ-5D scores were associated
with higher DLQI scores, a ﬁnding that was consistent with and
similar to the results of many previous studies.25,41,42 The VAS was
also negatively related to every DLQI domain (p < 0.01), a result
consistent with and similar to those of other studies.12,41
Finally, negative correlations between the TTO and most of the
DLQI domains were also consistent with results reported by
Lundberg et al,12 which indicated that the higher the TTO, the lower
the level of each aspect of QOL, as deﬁned by the DLQI domains.
However, there were differences in the statistical signiﬁcance of the
correlations between the TTO and two of the DLQI domains. First,
our study showed that the TTO and the “personal relationships”
domainwere negatively correlated at a statistically signiﬁcant level
of 0.01, indicating that respondents with poorer personal re-
lationships would be willing to exchange more life years for perfect
health. The “personal relationships” domain was deﬁned using the
following questions: “how much has your skin created problems
with your partner or any of your close friends or relatives?” and
“how much has your skin caused any sexual difﬁculties?” When a
disease is visible, even if it is noncontagious, social activities of
patients might be affected because of changes in appearance.43
Compared with previous studies of Caucasian psoriasis patients,
the impacts of psoriasis on relationships with family, friends, and
sexual partners among Taiwanese patients were better reﬂected in
the results of the TTO.12 This may have been due to the fact that
Taiwanese people in general are less aware of the noncontagious
nature of psoriasis, which results in poorer personal relationships
and a stigma associated with Taiwanese psoriasis patents. Second,
in our study, the negative correlation between the TTO and the
“treatment” domain did not reach statistical signiﬁcance. The
distress caused by treatment was deﬁned by the followingwith mild psoriasis.
Willingness to pay
117) Maximum WTP (n ¼ 106) Regression-adjusted WTP (n ¼ 106)
0.133 0.236*
0.257** 0.011
0.282** 0.155
0.016 0.114
0.221* 0.11
0.148 0.076
0.246* 0.047
trade-off; VAS ¼ visual analog scale; WTP ¼ willingness to pay.
Table 5 Health state utilities, WTP, and their associations with the DLQI among patients with moderate psoriasis.
Health utilities Willingness to pay
EQ-5D (n ¼ 208) VAS (n ¼ 208) TTO (n ¼ 208) Maximum WTP (n ¼ 199) Regression-adjusted WTP (n ¼ 199)
Symptoms & feelings 0.302** 0.339** 0.037 0.034 0.349**
Daily activities 0.227** 0.263** 0.169* 0.053 0.127
Leisure 0.322** 0.255** 0.094 0.097 0.039
Work & school 0.207** 0.167* 0.032 0.022 0.142*
Personal relationships 0.238** 0.253** 0.122 0.066 0.001
Treatment 0.245** 0.171* 0.009 0.001 0.096
Overall DLQI score 0.361** 0.346** 0.111 0.049 0.182*
* Statistically signiﬁcant at the 0.05 level (2 tailed).
** Statistically signiﬁcant at the 0.01 level (2 tailed).
DLQI ¼ Dermatology Life Quality Index; EQ-5D ¼ EuroQOL-ﬁve dimensions; TTO ¼ time trade-off; VAS ¼ visual analog scale; WTP ¼ willingness to pay.
Table 6 Health state utilities, WTP, and their associations with the DLQI among patients with severe psoriasis.
Health utilities Willingness to pay
EQ-5D (n ¼ 155) VAS (n ¼ 155) TTO (n ¼ 155) Maximum WTP (n ¼ 149) Regression-adjusted WTP (n ¼ 149)
Symptoms & feelings 0.421** 0.314** 0.174* 0.027 0.107
Daily activities 0.361** 0.262** 0.159* 0.084 0.115
Leisure 0.379** 0.263** 0.153 0.013 0.243**
Work & school 0.322** 0.230** 0.08 0.071 0.069
Personal relationships 0.208** 0.121 0.175* 0.021 0.032
Treatment 0.236** 0.146 0.127 0.024 0.315**
Overall DLQI score 0.428** 0.298** 0.196* 0.034 0.192*
* Statistically signiﬁcant at the 0.05 level (2 tailed).
** Statistically signiﬁcant at the 0.01 level (2 tailed).
DLQI ¼ Dermatology Life Quality Index; EQ-5D ¼ EuroQOL-ﬁve dimensions; TTO ¼ time trade-off; VAS ¼ visual analog scale; WTP ¼ willingness to pay.
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time.” This indicated that respondents with greater distress caused
by treatment were not willing to give up more years of life in ex-
change for perfect health, which was possibly due to the conve-
nience of accessing medical resources in Taiwan resulting from the
nation's national health insurance program. This seems to indicate
that the TTO is not a valid measure for reﬂecting the distress caused
by psoriasis treatment.
The results of our study further showed that the maximumWTP
had signiﬁcant positive correlations with the “leisure” and “per-
sonal relationships” domains, and with the overall DLQI score. This
suggests that, among Taiwanese psoriasis patients, the impacts of
social activities on QOL were particularly well reﬂected in the
maximum WTP. By contrast, Lundberg et al12 found that only the
“treatment” domain had a signiﬁcant positive correlation with the
maximum WTP. Furthermore, they found that the correlations of
the other domains with the maximumWTP were not signiﬁcant or
were even negative.
The RA-WTP had signiﬁcantly positive correlations with all the
domains of the DLQI, which is largely consistent with the ﬁndings
of previous studies.24,26 Lundberg et al,12 for example, found that
the regression-based WTP had positive correlations with the DLQI
domains; however, the correlations with the “work and school” and
“personal relationships” domains did not achieve statistical sig-
niﬁcance. Nonetheless, the results of this study showed that the
RA-WTP can be used to reﬂect the QOL in each DLQI domain among
Taiwanese patients with psoriasis.
The mean and median RA-WTP values in our study were
US$218.9 and US$249.5, respectively. These results are similar to
the results reported by Lundberg et al12 (US$157.8e246.3 per
month). By contrast, a study conducted by Finlay and Coles44
showed that patients with severe psoriasis were willing to pay
US$6752.8 per month on average. This was much higher than the
WTP of patients with severe psoriasis in our study. This disparity
might have been due to (1) differences in disease severity, (2) dif-
ferences in perceptions of QOL between developed and developing
countries, and (3) the 15-year gap between the two studies.When patients were divided into the three groups of mild,
moderate, and severe psoriasis, the results indicated that the DLQI
domains remained strongly correlated with the EQ-5D and VAS in
the three patient subgroups; however, the correlations between the
TTO and each DLQI domain changed after stratiﬁcation by severity
of disease. In patients with mild psoriasis, the TTO had signiﬁcant
negative correlations with only the “leisure” and “personal re-
lationships” domains, as well as with the overall DLQI score. The
TTO of patients with moderate psoriasis had a signiﬁcant negative
correlation only with the “daily activities” domain. For patients
with severe psoriasis, the TTO had signiﬁcant negative correlations
with the “symptoms and feelings,” “daily activities,” and “personal
relationships” domains, as well as with the overall DLQI score.
After stratiﬁcation by severity of disease, an increased number
of DLQI domains showed a signiﬁcant positive correlation with the
maximum WTP in patients with mild psoriasis. These were the
“daily activities,” “leisure,” and “personal relationships” domains, in
addition to the overall DLQI score. ThemaximumWTP and the DLQI
domains were not signiﬁcantly correlated in patients with moder-
ate and severe psoriasis.
The RA-WTP and DLQI domains showed negative correlations
and even achieved signiﬁcant levels in patients with mild and
moderate psoriasis. It might be that the RA-WTPwas not applicable
to patients with mild and moderate psoriasis; however, there were
positive correlations of the RA-WTP with DLQI domains in patients
with severe psoriasis. In particular, the “leisure” and “treatment”
domains, as well as the overall DLQI score, achieved statistical
signiﬁcance. It could therefore be inferred that the RA-WTP is more
applicable in measuring the QOL of patients with severe psoriasis.
In our study, the average score of the DLQI was 8.34 for all three
disease severity levels combined. This was similar to the results of a
German study in which the average score was 8.6.25 The study
conducted by Lundberg et al12 in patients with mild psoriasis found
that the average score of the DLQI was 5.93. This was similar to the
results of our study, which showed the DLQI of patients with mild
psoriasis to be 5.73. Our study also showed that disease severity
was signiﬁcantly correlated with most of the DLQI domains. The
W.-C. Ko et al. / Dermatologica Sinica 34 (2016) 185e191190degree of correlation between the PASI and DLQI found in the
studies conducted by Touw et al45 and Salek et al46 on the efﬁcacy of
medications used by patients was also similar to that found in our
study. Our study found that after other variables were controlled
for; personal relationships of patients withmoderate psoriasis were
noworse than those of patientswithmild psoriasis. Thismight have
been due to the fact that personal relationships are a psychological
indicator, while the PASI is a clinical indicator. The PASI is not a good
indicator for predicting psychological QOL.47,48 Therefore, the dif-
ference in scores in the domain of “personal relationships” of pa-
tients with mild and moderate psoriasis was not signiﬁcant.
The severity of psoriasis was deﬁned by the PASI in our study.
However, there is some debate as to what deﬁnes mild, moderate,
and severe psoriasis. In addition, the correlation of PASI scores
with body surface area involvement is not linear, especially for
lesions of < 10% of the body surface area. Although the partici-
pants in our study consisted of patients from northern, central,
and southern Taiwan, they do not represent all the affected pa-
tients in Taiwan. The other limitation is that all the study partic-
ipants were recruited from hospitals, and patients who seek
treatment at hospitals may be different from those who receive
treatment at private practices, from practitioners of Chinese
medicine, or in pharmacies.
A high PASI score was associated with high DLQI scores. How-
ever, even with mild psoriasis, 39.4% of patients reported at least
moderate effects on their QOL. A considerable overlap in terms of
the WTP existed for moderate and severe psoriasis patients, which
may reﬂect a similar effect on QOL among the two groups of pa-
tients. In addition, our results indicate that both the EQ-5D and the
VAS can be chosen as measurement instruments for use in Taiwa-
nese patients with psoriasis to assess the costs and consequences of
treatment options. By contrast, the TTO seems to be a less valid
instrument for distinguishing QOL among patients with psoriasis,
especially those with mild psoriasis.
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